SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001628280-24-000199
Filing Date
2024-01-03
Accepted
2024-01-03 16:18:12
Documents
13
Period of Report
2023-12-29
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K fhtx-20231229.htm   iXBRL 8-K 32825
2 EX-99.1 exhibit991foghorncfodepart.htm EX-99.1 9390
  Complete submission text file 0001628280-24-000199.txt   175063

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT fhtx-20231229.xsd EX-101.SCH 1907
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT fhtx-20231229_lab.xml EX-101.LAB 24846
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT fhtx-20231229_pre.xml EX-101.PRE 13047
7 EXTRACTED XBRL INSTANCE DOCUMENT fhtx-20231229_htm.xml XML 2829
Mailing Address 500 TECHNOLOGY SQUARE SUITE 700 CAMBRIDGE MA 02139
Business Address 500 TECHNOLOGY SQUARE SUITE 700 CAMBRIDGE MA 02139 617-586-3100
Foghorn Therapeutics Inc. (Filer) CIK: 0001822462 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39634 | Film No.: 24506663
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)